Regulus Therapeutics Inc.’s (RGLS) share price has entered into oversold territory with an RSI value of 29.23. The Zacks Consensus Estimate on Regulus Therapeutics Inc.’s earnings for the full year period has loss of 0.00 cents over the past two months to $-0.74 per share. Currently, Regulus Therapeutics Inc. is a Zacks #2 Rank (“Buy”), suggesting that now might be a good time to get in on (RGLS) after its recent drop.
REGULUS THERAPEUTICS INC (RGLS): Free Stock Analysis Report
Zacks Investment Research